(9ci)-1H-2-苯并吡喃-1-羧醛 | 148679-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: (9ci)-1H-2-苯并吡喃-1-羧醛
• 英文名称: 1H-2-benzopyrano-1-carboxaldehyde
• 英文别名: 1H-2-benzopyran-1-carboxaldehyde；1H-isochromene-1-carbaldehyde
• CAS: 148679-89-4
• 化学式: C₁₀H₈O₂
• mdl: MFCD18807183
• 分子量: 160.172
• InChiKey: XCNJKTGJKDKMEC-UHFFFAOYSA-N

物化性质

• 沸点：
  320.2±42.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4,5-benzoxepin 在 二甲基二环氧乙烷 作用下， 以 丙酮 为溶剂， 生成 (9ci)-1H-2-苯并吡喃-1-羧醛
  参考文献：
  名称：

  通过1 H NMR直接观察到4,5-苯并氧杂-2,3-氧化物及其令人惊讶的快速开环重排为1 H -2-苯并吡喃-1-甲醛

  摘要：

  据报道，oxepin-2,3-氧化物的第一个明确观察。在5至10°C之间，它迅速重排为异构体1 H -2-苯并吡喃-1-甲醛。相反，单环氧杂环丁烷的2，3-氧化物重新排列成稳定的，开环的二醛或二酮。

  DOI：

  10.1016/j.tetlet.2004.04.081

文献信息

• NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20120157459A1

  公开（公告）日：2012-06-21

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR 7 —; and R 1 to R 7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  提供一个以新型化合物作为活性成分的GPR40激活剂，该化合物具有GPR40激动剂作用，该化合物的盐，该盐或化合物的溶剂合物，或者类似物，尤其是胰岛素分泌促进剂以及对糖尿病、肥胖症或其他疾病的预防及/或治疗剂。[解决该问题的方法] 公式(I)的化合物：（其中n为0至2；p为0至4；j为0至3；k为0至2；环A是一个芳基团，可选择性被L取代或是一个杂环团，可选择性被L取代；环B是一个苯环、一个吡啶环或一个嘧啶环；X是O，S，—NR7—；R1至R7是特定基团），该化合物的盐，或该盐或化合物的溶剂合物。
• NOVEL ARYL UREA DERIVATIVE
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：EP2518064A1

  公开（公告）日：2012-10-31

  There is a need for FAAH inhibitors capable of oral administration and having excellent efficacy, particularly agents for the prevention and treatment of pain. Disclosed are novel arylurea compounds represented by formula (I), salts or solvates thereof, and pharmaceutical compositions comprising the same as an active ingredient. The pharmaceutical composition is used primarily for FAAH inhibitors, or agents for prevention and treatment of pain.

  需要具有口服能力且具有出色疗效的FAAH抑制剂，特别是用于预防和治疗疼痛的药物。揭示了由式(I)表示的新型芳基脲类化合物，其盐或溶剂，以及包含其作为活性成分的药物组合物。该药物组合物主要用于FAAH抑制剂，或用于预防和治疗疼痛的药物。
• NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20120220772A1

  公开（公告）日：2012-08-30

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH 2 —, O, —S(O) i — (i is 0 to 2), or —NR 7 —; R 1 to R 6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  提供一种GPR40激活剂，其作为活性成分具有一种具有GPR40激动剂作用的新化合物，该化合物的盐、盐或化合物的溶剂或类似物，特别是一种胰岛素分泌促进剂以及预防和/或治疗糖尿病、肥胖或其他疾病的药物。 通过以下公式(I)的化合物解决问题： （其中p为0至4；j为0至3；k为0至2；环A为特定的环状基团；环B为苯环、吡啶环或嘧啶环；X为—CH2—、O、—S(O)i—（i为0至2）或—NR7—；R1至R6为特定的基团），该化合物的盐或盐的溶剂。
• CYCLIC AMIDE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20130203739A1

  公开（公告）日：2013-08-08

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR 7 —; J 1 is —CR 11a R 11b — or —NR 11c —; J 2 is —CR 12a R 12b — or —NR 12c —; and R 1 to R 12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  为提供一种具有GPR40激活剂作用的新化合物、该化合物的盐、盐或化合物的溶剂合物，尤其是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药剂，解决问题的方法是使用Formula (1)的化合物：(其中n为0至2；p为0至4；h为0至3；j为0至3；k为0至2；环B为芳香族或杂环芳基；X为O、S或-NR7-；J1为-CR11aR11b-或-NR11c-；J2为-CR12aR12b-或-NR12c-；R1到R12为特定基团)，该化合物的盐，或盐或化合物的溶剂合物。
• [EN] TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS<br/>[FR] COMPOSE DE BENZOPYRANNE TRICYCLIQUE EN TANT QU'AGENTS ANTI-ARRYTHMIQUES
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2005090357A1

  公开（公告）日：2005-09-29

  This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R1 and R2 are independently of each other hydrogen atom, C1-6alkyl group or C6-14aryl group, R3 is hydrogen atom or C1-6alkylcarbonyloxy group, or together with R4 forms a bond, R4 is hydrogen atom, or together with R3 forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR7R8, NR9, O, S, SO or SO2, R5 is hydrogen atom or C1-6alkyl group, R6 is hydrogen atom, C1-6alkyl group, C3-8cycloalkyl group, C3-8cycloalkenyl group, amino group, C1-6alkylamino group, di-C1-6alkylamino group, C6-14arylamino group, C2-9heteroarylamino group, C6-14aryl group, C2-9heteroaryl group or C2-9heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.

  本发明涉及公式（I）或（II）的苯并吡喁衍生物，或其药学上可接受的盐，其中R1和R2分别是氢原子、C1-6烷基或C6-14芳基，R3是氢原子或C1-6烷基羰氧基，或与R4一起形成键，R4是氢原子，或与R3一起形成键，m是0到4的整数，n是0到4的整数，V是单键，CR7R8，NR9，O，S，SO或SO2，R5是氢原子或C1-6烷基，R6是氢原子，C1-6烷基，C3-8环烷基，C3-8环烯基，氨基，C1-6烷基氨基，二C1-6烷基氨基，C6-14芳基氨基，C2-9杂芳基氨基，C6-14芳基，C2-9杂芳基或C2-9杂环烷基，A是与苯环融合的5、6或7成员环，作为环的组成原子，氧原子、氮原子或硫原子可以单独或组合地包含在其中，环中的不饱和键数为1、2或3，包括与苯环融合的不饱和键，构成环的碳原子可以是羰基或硫代羰基。这些化合物可用作抗心律失常药物。